Clinical Trials Browser

Phase 2 × dabrafenib × 90 days × Clear all

NCT03149029 2026-04-21

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Phase 2 Active not recruiting

16 enrolled 10 charts

Melanoma

NCT02196181 2026-04-13

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

Phase 2 Active not recruiting

Melanoma

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03919071 2026-04-13

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Phase 2 Active not recruiting

Astrocytoma, Glioblastoma, Glioma

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

Phase 2 Active not recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02693535 2026-04-02

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03244956 2026-03-23

MERAIODE

Phase 2 Completed

EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

Phase 2 Active not recruiting

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Phase 2 Active not recruiting

Melanoma